T1	Phenotype	24 41	symptom endpoints
T2	Pharmacodynamic_phenotype	63 83	efficacy outcomes in
T3	Chemical	102 114	gefitinib in
T4	Disease	129 162	EGFR mutation-positive tumors and
T5	Chemical	163 190	carboplatin / paclitaxel in
T6	Disease	210 236	mutation-negative tumors .
R1	isAssociatedWith	Arg1:T1	Arg2:T2
R2	isAssociatedWith	Arg1:T1	Arg2:T3
R3	isAssociatedWith	Arg1:T1	Arg2:T4
R4	isAssociatedWith	Arg1:T1	Arg2:T5
R5	isAssociatedWith	Arg1:T1	Arg2:T6
R6	isAssociatedWith	Arg1:T2	Arg2:T1
R7	influences	Arg1:T2	Arg2:T3
R8	influences	Arg1:T2	Arg2:T5
R9	isAssociatedWith	Arg1:T2	Arg2:T6
R10	treats	Arg1:T3	Arg2:T1
R11	treats	Arg1:T3	Arg2:T4
R12	treats	Arg1:T3	Arg2:T5
R13	treats	Arg1:T3	Arg2:T6
R14	treats	Arg1:T4	Arg2:T1
R15	isAssociatedWith	Arg1:T4	Arg2:T2
R16	influences	Arg1:T4	Arg2:T3
R17	treats	Arg1:T4	Arg2:T6
R18	treats	Arg1:T5	Arg2:T1
R19	influences	Arg1:T5	Arg2:T3
R20	treats	Arg1:T5	Arg2:T4
R21	treats	Arg1:T5	Arg2:T6
R22	isAssociatedWith	Arg1:T6	Arg2:T1
R23	isAssociatedWith	Arg1:T6	Arg2:T2
R24	influences	Arg1:T6	Arg2:T3
R25	treats	Arg1:T6	Arg2:T4
R26	influences	Arg1:T6	Arg2:T5
